Arixtra

In the US, Arixtra (fondaparinux systemic) is a member of the drug class factor Xa inhibitors and is used to treat Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis - Prophylaxis and Pulmonary Embolism.

US matches:

• Arixtra

UK matches:

• Arixtra 1.5 mg/0.3 ml solution for injection, pre-filled syringe (SPC)
• Arixtra 2.5mg/0.5ml solution for injection, pre-filled syringe. (SPC)
• Arixtra 5mg, 7.5mg, 10mg solution for injection, pre-filled syringe (SPC)

Ingredient matches for Arixtra

Fondaparinux

Fondaparinux Sodium is reported as an ingredient of Arixtra in the following countries:

• Antigua & Barbuda


• Aruba


• Australia


• Austria


• Bahamas


• Barbados


• Belgium


• Bermuda


• Canada


• Cayman Islands


• China


• Colombia


• Costa Rica


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Dominican Republic


• El Salvador


• Finland


• France


• Germany


• Greece


• Grenada


• Guatemala


• Guyana


• Honduras


• Hungary


• Iceland


• Indonesia


• Italy


• Jamaica


• Luxembourg


• Malaysia


• Mexico


• Netherlands


• Netherlands Antilles


• Norway


• Oman


• Panama


• Peru


• Portugal


• Russian Federation


• Saint Lucia


• Singapore


• Slovakia


• Slovenia


• South Africa


• Spain


• Sweden


• Switzerland


• Thailand


• Trinidad & Tobago


• Turkey


• United Kingdom


• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.